Tag
Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to adv
Achieving disease clearance early after induction therapy with ustekinumab in ulcerative colitis patients predicts sustained clinical remission, symptom control, and improved quality of life over four years.
This longitudinal study reveals persistent cognitive, physical, and vascular challenges up to 9 years after minor lacunar or cortical ischemic stroke, emphasizing different risks and recovery patterns by stroke subtype.
Active surveillance is a durable management strategy for small, low-risk papillary thyroid cancer, especially among older adults who show significantly lower crossover rates to surgery.
Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.
A multicenter study reveals that 30% of adult VA-ECMO patients survive 12 months without new disability, with most disability developing within the first 6 months. Functional independence and employment improve by 12 months post-ECMO.
A multicenter randomized trial shows POEM is non-inferior to LHM plus Dor fundoplication for achalasia symptom control at 5 years, with differing reflux profiles.
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Large-scale UK data reveal a transient increase but sustained long-term reduction in fracture risk after discontinuing menopausal HRT, challenging prior assumptions and guiding future clinical decisions.
